Pantherna Therapeutics GmbH, a mRNA-lipid nanoparticle (LNP) platform company dedicated to the research and development of innovative mRNA-based therapeutics today announced a research collaboration with Bayer, investigating novel LNP-carriers for future mRNA therapies outside the liver. By combining their expertise in RNA therapeutics, both parties intend to identify novel LNP formulations that surpass the performance of conventional neutral LNPs as used in the mRNA vaccines. These advanced LNPs will be designed to potentially offer superior properties, ensuring the desired pharmacological outcomes and facilitating a smooth scalable translation towards development.

Ansgar Santel, CEO of Pantherna Therapeutics, commented “Pantherna values Bayer’s trust in our technology and expertise. In collaboration, we will explore the potential of novel LNP formulations tailored to Bayer’s therapeutic interest, accelerating the pace of innovation and enhancing patient care. We look forward to partnering with the Bayer Non-Viral Delivery team.”